Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

LRRK2 antibody (Leucine-Rich Repeat Kinase 2) (AA 931-962) Primary Antibody

LRRK2 Reactivity: Human IHC (p), WB Host: Rabbit Polyclonal RB7199 unconjugated
Pubmed (4)
Catalog No. ABIN1882109
$423.50
Plus shipping costs $45.00
400 μL ABIN1882109
400 μL ABIN1882109
local_shipping Shipping to: United States
Delivery in 10 to 11 Business Days
  • Target
    LRRK2
    Binding Specificity
    • 5
    • 2
    • 2
    • 1
    • 1
    AA 931-962
    Reactivity
    • 10
    • 7
    Human
    Host
    • 7
    • 3
    Rabbit
    Clonality
    • 7
    • 3
    Polyclonal
    Application
    • 9
    • 5
    • 3
    • 2
    • 1
    • 1
    Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
    Purification
    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
    Immunogen
    This PARK8(LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 931-962 amino acids from human PARK8(LRRK2).
    Clone
    RB7199
    Isotype
    Ig Fraction
  • Application Notes
    WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C,-20 °C
    Expiry Date
    6 months
  • Biskup, Moore, Rea, Lorenz-Deperieux, Coombes, Dawson, Dawson, West: "Dynamic and redundant regulation of LRRK2 and LRRK1 expression." in: BMC neuroscience, Vol. 8, pp. 102, 2008 (PubMed). Method employed by authors: Western Blotting (WB)

    Shen: "Protein kinases linked to the pathogenesis of Parkinson's disease." in: Neuron, Vol. 44, Issue 4, pp. 575-7, 2004 (PubMed).

    Wszolek, Pfeiffer, Tsuboi, Uitti, McComb, Stoessl, Strongosky, Zimprich, Müller-Myhsok, Farrer, Gasser, Calne, Dickson: "Autosomal dominant parkinsonism associated with variable synuclein and tau pathology." in: Neurology, Vol. 62, Issue 9, pp. 1619-22, 2004 (PubMed).

    Zimprich, Biskup, Leitner, Lichtner, Farrer, Lincoln, Kachergus, Hulihan, Uitti, Calne, Stoessl, Pfeiffer, Patenge, Carbajal, Vieregge, Asmus, Müller-Myhsok, Dickson, Meitinger, Strom, Wszolek, Gasser: "Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology." in: Neuron, Vol. 44, Issue 4, pp. 601-7, 2004 (PubMed).

  • Target
    LRRK2
    Alternative Name
    PARK8 (LRRK2) (LRRK2 Antibody Abstract)
    Synonyms
    LRRK2, AURA17, DARDARIN, PARK8, RIPK7, ROCO2, 4921513O20Rik, 9330188B09Rik, AW561911, D630001M17Rik, Gm927, cI-46, leucine-rich repeat kinase 2, leucine rich repeat kinase 2, lrrk2, LRRK2, Lrrk2
    Background
    Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.
    Molecular Weight
    286103
    NCBI Accession
    NP_940980
    UniProt
    Q5S007
    Pathways
    Regulation of G-Protein Coupled Receptor Protein Signaling, Skeletal Muscle Fiber Development
You are here:
help Support